A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93

Mark T. Orr1, Elyse A. Beebe1, Thomas E. Hudson1, James J. Moon2, Christopher B. Fox1, Steven G. Reed1, Rhea N. Coler1,3*

1Infectious Disease Research Institute, Seattle, Washington, United States of America, 2Center for Immunology and Inflammatory Diseases and Pulmonary and Critical Care Unit, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America, 3Department of Global Health, University of Washington, Seattle, Washington, United States of America

Abstract

With over eight million cases of tuberculosis each year there is a pressing need for the development of new vaccines against Mycobacterium tuberculosis. Subunit vaccines consisting of recombinant proteins are an attractive vaccine approach due to their inherent safety compared to attenuated live vaccines and the uniformity of manufacture. Addition of properly formulated TLR agonist-containing adjuvants to recombinant protein vaccines enhances the antigen-specific CD4+ T cell response characterized by IFN-γ and TNF, both of which are critical for the control of TB. We have developed a clinical stage vaccine candidate consisting of a recombinant fusion protein ID93 adjuvanted with the TLR4 agonist GLA-SE. Here we examine whether ID93+GLA-SE can be improved by the addition of a second TLR agonist. Addition of CpG containing DNA to ID93+GLA-SE enhanced the magnitude of the multi-functional Tc1 response against ID93 characterized by co-production of IFN-γ, TNF, and IL-2. Addition of CpG also improved the protective efficacy of ID93+GLA-SE. Finally we demonstrate that this adjuvant synergy between GLA and CpG is independent of TRIF signaling, whereas TRIF is necessary for the adjuvant activity of GLA-SE in the absence of CpG.

Introduction

Approximately two billion people are infected with Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB). In 2011 there were over 8 million cases of active TB leading to 1.5 million deaths worldwide. The only vaccine against TB, BCG limits childhood disease, but is variably effective against pulmonary TB in adults, with efficacy estimates ranging from 0 to 80% [1]. Thus there is a pressing need for new vaccine candidates against this devastating disease. In the last decade there has been considerable effort to develop new candidate vaccines against TB, with several entering clinical testing [2].

M.tb is primarily controlled by Th1 cells producing IFN-γ and TNF that activate infected macrophages, as well as IL-2 which sustains the T cell response [3]. This has led to the hypothesis that the magnitude of the multifunctional Th1 cells (i.e. cells producing IFN-γ, TNF, and IL-2) is important for an effective vaccine response against M.tb [4]. Thus enhancing the magnitude of the Th1 response against candidate vaccine antigens is critical for developing an effective vaccine against TB. We have developed a clinical candidate antigen, ID93, which is a fusion of four M.tb proteins: Rv1813, Rv2608, Rv3619, and Rv3620. When paired with the adjuvant GLA-SE, prophylactic immunization with ID93+GLA-SE limits M.tb. in mice and guinea pigs [5].

Therapeutic vaccination with ID93+GLA-SE is an effective adjunct to chemotherapy in M.tb infected mice and non-human primates [6]. The adjuvant GLA-SE contains the synthetic TLR4 agonist GLA formulated in a stable oil-in-water nano-emulsion (SE) [7,8]. In the absence of GLA, ID93 formulated in SE elicits a weak, non-protective Th12 response in mice. Therefore inclusion of a TLR4 agonist is essential for the efficacy of this vaccine [9]. Additionally the nature of the vaccine formulation can have profound effects on both the immunogenicity and efficacy of ID93+GLA-SE [10]. ID93+GLA-SE is currently undergoing Phase I clinical testing [11].

Although TLR4 agonists such as GLA and monophosphoryl lipid (MPLA) are the most clinically advanced TLR agonist adjuvants for vaccines, with MPLA included in several licensed vaccines, other TLR agonists are also being developed as vaccine adjuvants [12–15]. Additionally there is substantial interest in combining TLR agonists as vaccine adjuvants to enhance immunogenicity and efficacy. In vitro and in vivo studies have found that certain combinations of TLR agonists can cooperate to enhance cytokine and chemokine production by professional antigen presenting cells such as dendritic cells and macrophages, whereas other combinations of agonists can impair vaccine efficacy [16–18]. Several groups have found that combining two or three TLR agonists can enhance Th1 cell and antibody responses against experimental
vaccines [17,19–21]. In our own work we have shown that combining MPLA or GLA with a TLR9 agonist CpG enhances the efficacy of a candidate therapeutic vaccine against _Leishmania_ [22].

The different TLRs signal either through MyD88 (TLR2, TLR3, TLR7, TLR8 and TLR9), TRIF (TLR3) or both signaling pathways (TLR4) [23]. Effective enhancement of adjuvant activity with multiple TLR agonists is most often seen with combinations of agonists that activate the TRIF pathway with agonists that activate the MyD88 pathway. This has led to the hypothesis that MyD88 and TRIF cooperation is necessary for enhanced adjuvant activity with a combination of TLR agonists [16,17,24]. We present evidence that combining TLR4 and TLR9 agonists enhances the Th1 response against ID93 and leads to increased protection against aerosolized _M.tb._ challenge. Further we explore the contribution of TRIF to this enhanced immunogenicity.

**Materials and Methods**

**Ethics statement**

The study was conducted under protocol number 2011/5 approved by the Infectious Disease Research Institute Institutional Animal Care and Use Committee.

**Animals and immunizations**

6–8 week old female C57BL/6 mice were purchased from Charles River and The Jackson Laboratory and maintained in Specific Pathogen Free conditions. TRIF−/− (also known as _Ticam1−/−_) breeder mice on the C57BL/6 background were purchased from The Jackson Laboratory and bred in-house. After infection animals were maintained in ABSL3 containment. Mice were immunized three times three weeks apart by intramuscular injection. Each immunization contained 0.5 μg of ID93 recombinant protein [5] with 5 μg of GLA (Avanti Polar Lipids), 8 μg of CpG1826 (Oligos, Etc.), or both. Adjuvants were formulated in RPMI 1640 and 10% FBS. Cells were plated at 2×10⁶ cells/well in 96-well plates and were stimulated for 1 hour with media containing 5×10⁶ CFU (Pasteur strain, Sanofi Pasteur) were injected intradermally once at the time of the first subunit immunization.

**Intracellular cytokine staining**

One week after the final immunization splenocytes were isolated from three to five animals per group. Red blood cells were lysed using Red Blood Cell Lysis Buffer (eBioscience) and resuspended in RPMI 1640 and 10% FBS. Cells were plated at 2×10⁶ cells/well in 96-well plates and were stimulated for 1 hour with media containing 1 μg/ml of MyD88 recombinant protein [5] with 5 μg of GLA (Avanti Polar Lipids), 8 μg of CpG1826 (Oligos, Etc.), or both. Adjuvants were formulated in-house in IDRI’s stable emulsion (SE), as described previously [8]. For BCG immunization 5×10⁶ CFU (Pasteur strain, Sanofi Pasteur) were injected intradermally once at the time of the first subunit immunization.

**Statistical methods**

Bacterial burdens were normalized by log₁₀ transformation. Statistical significance of differences in bacterial burden and cytokine production were determined by analysis of variance using SPICE version 5.2, downloaded from <http://exon.niaid.nih.gov/spice>.

**MHC class II tetramer production and staining**

ID93-specific I-A^b^ tetramers with the immunodominant epitope from _Rv3619_ (VYEQQANAHGQ) and _Rv2608_ (AVLPPFVEVNSA) were produced using methods previously described [25,26]. One week after the final immunization splenocytes were isolated as described above. Cells were then stained for one hour at room temperature with 10 μM tetramer. Cells were washed and stained for surface CD4, CD8, and CD44. Up to 10⁶ events were collected on a four laser LSRII Fortessa flow cytometer (BD Biosciences). Cells were gated as singlets > lymphocytes > CD4^+^ CD8^-^ > CD44^+^ > cytokine positive. Analysis and presentation of distributions was performed using FlowJo. Cells were gated as singlets > lymphocytes > CD4^+^ CD8^-^ > CD44^+^ > cytokine positive.
the Bonferroni correction for multiple comparisons using Prism 5 (GraphPad Software).

**Results**

Enhanced TH1 responses to ID93 with the combination adjuvant GLA and CpG

To determine whether a combined CpG and GLA adjuvant would enhance the CD4+ T cell response to ID93 we immunized C57BL/6 mice with ID93 adjuvanted with GLA, CpG, or both. All vaccines were formulated as stable nanodroplet emulsions (SE) [8]. One week after the third immunization we determined the frequency of CD4+ T cells specific for two immunodominant epitopes of ID93 by MHC class II tetramer staining. ID93+GLA-SE elicited greater frequencies of ID93-specific CD4+ T cells compared to ID93+GLA-SE (Figure 1A and B). Combining the two TLR agonists further enhanced the frequency of ID93-specific CD4+ T cells. When splenocytes were stimulated with ID93 and assessed for cytokine production we found that ID93+GLA-SE and ID93+CpG-SE elicited similar frequencies of CD4+ T cells producing IFN-γ, TNF, or IL-2 (Figure 1C). We did not detect appreciable levels of IL-17 or IL-5 producing cells from these immunizations (data not shown). Combining GLA and CpG more than doubled the frequency of cytokine producing CD4+ T cells (Figure 1C). To determine the extent of multi-functionality of these ID93 specific cells we analyzed the frequency of cells making all combinations of IFN-γ, TNF, and IL-2. The overall distribution of cells was similar across all three immunization regimens, with ID93+CpG/GLA-SE eliciting more cells in all categories (Figure 1D). The vast majority of ID93-specific CD4+ T cells produced both IFN-γ and TNF with approximately half of these cells also producing IL-2. Taken together these data demonstrate that the combination adjuvant CpG/GLA-SE augments production of multi-functional TH1 cells to a greater extent than either GLA-SE or CpG-SE.

GLA and CpG cooperate to enhance the protective efficacy of ID93

Although IFN-γ and TNF are critical for control of M.tb., there are conflicting reports regarding the correlation between the magnitude of IFN-γ and TNF producing T cells elicited by vaccination and the degree of protective efficacy [3,28–30]. To determine whether the enhanced TH1 response generated by ID93+CpG/GLA-SE resulted in more substantial protection against M.tb. we challenged immunized mice with a low dose of aerosolized M.tb. one month after the final immunization. ID93+GLA-SE and ID93+CpG-SE immunization both conferred substantial protection against M.tb. challenge (P<0.001 and
Combining the two immunostimulants into the same adjuvant formulation further reduced the \textit{M. tb}. burden in the lungs of infected mice to a level induced by BCG immunization (Figure 2A). To determine whether this enhanced protective response was long lasting we challenged a second cohort of immunized mice three months after the final immunization. Again we found that ID93 + GLA-SE and ID93 + CpG-SE both limited the \textit{M. tb}. burden in the lungs (Figure 2B). The combination adjuvant further reduced the bacterial burden at this late time point, indicating that this superior protective efficacy was durable and significant.

We also assessed cellular infiltration and lung pathology in the animals challenged four weeks after immunization. In unimmunized animals there was a significant reduction in free airway space and substantial numbers of loosely aggregated granulomatous structures (Figure S2). Immunization with ID93 + GLA-SE or ID93 + CpG-SE resulted in greater free airway space, and fewer areas of consolidated granulomas, however the granulomas that developed were more structured than those seen in the unimmunized animals. Immunization with ID93 + CpG/GLA-SE extended this protective benefit, with little sign of consolidated areas in the lungs (Figure S2). Overall these data indicate that the enhanced \textit{T}H1 response elicited with the combined \textit{CpG/GLA-SE} adjuvant with ID93 correlated with enhanced protection both in terms of reduced bacterial burden and limited lung pathology.

**TRIF is not necessary for enhanced immunogenicity with the combined GLA and CpG adjuvant**

Both MyD88 and TRIF are necessary for the adjuvant activity of GLA-SE [31]. To determine whether TRIF signaling is necessary for GLA to augment the adjuvant activity of CpG-SE we compared the cytokine production by C57BL/6 and TRIF-deficient splenic macrophages stimulated with GLA, CpG, or both. In the absence of TRIF, GLA induction of IL-6, IL-12p40 and TNF was substantially impaired, whereas there was little impact on cytokine induction by CpG in the absence of TRIF (Figure 3A). The combination of GLA and CpG enhanced production of these cytokines in C57BL/6 macrophages and surprisingly this additive effect was also present in TRIF-deficient macrophages, indicating that TRIF may not be necessary for enhanced adjuvant activity of the GLA and CpG combination.

To directly evaluate the contribution of TRIF signaling to the enhanced adjuvant activity of GLA and CpG we immunized B6 and TRIF-deficient mice with ID93 adjuvanted with GLA-SE, CpG-SE, or CpG/GLA-SE. As we saw previously (Figure 1) the combination of GLA and CpG enhanced the frequency of CD4$^+$ T cells producing IFN-\(\gamma\), TNF, and IL-2 upon restimulation with ID93 (Figure 3B and C). In the absence of TRIF, ID93+GLA-SE did not elicit ID93-specific \textit{T}H1 cells. In TRIF-deficient mice the magnitude of the \textit{T}H1 response elicited by the combination GLA and CpG adjuvant was substantially greater than that elicited by CpG alone (Figure 3B and C). Thus GLA and CpG cooperate to enhance the magnitude of the \textit{T}H1 response to immunization in a TRIF-independent fashion.

**Discussion**

TB remains one of the most clinically important infectious diseases globally. By examining the breadth of T cell responses to \textit{M. tb}. proteins found in infected patients and evaluating the potential for protection when delivered as a prophylactic vaccine we have identified a set of candidate antigens for inclusion in new subunit vaccine against TB. These antigens were initially identified as protective in animal models when they were paired with a CpG containing adjuvant [32]. We have found that these proteins are also protective when delivered with the TLR4 agonist adjuvant.
GLA-SE [5]. We now demonstrate that by combining CpG and GLA in the same adjuvant formulation we can further enhance the immunogenicity and protective efficacy of the ID93 vaccine antigen. Further we find that although GLA signaling via the TRIF pathway downstream of TLR4 is necessary for the adjuvant activity of GLA-SE, TRIF is dispensable for the cooperative benefit of combining GLA and CpG. Infections are first recognized by pattern recognition receptors (PRR) expressed by many cell types including professional APCs such as macrophages and dendritic cells, which prime T cell responses. PRR including TLR, RIG-I like receptors (RLR), C-type lectin receptors (CLR) and NOD-like receptors (NLR) recognize a diverse array of pathogen associated molecular patterns (PAMP). PRR engagement leads to professional APC maturation, increased antigen presentation and secretion of cytokines and chemokines that direct the magnitude and quality of the adaptive immune response [13]. Synthetic and naturally derived PRR agonists have been widely used to mimic infection and shape the immune response to recombinant proteins that would otherwise be poorly immunogenic or tolerogenic [33]. Many infections are detected by multiple PRRs, allowing the immune system to tailor the innate and adaptive immune response to the particular pathogen [34]. For example, *M. tuberculosis* is recognized by TLR2 (MDP), TLR9 (CpG DNA), Mincle (trehalose dimycolate) and NOD2 (MDP) [35].

Many studies have shown that triggering multiple PRR in vitro can result in additive, synergistic, or antagonistic effects on APC maturation and secretion of cytokines including IL-12, IL-6, and TNF [16,23,24,36–41]. This is true both of triggering multiple receptors in the same class, such as multiple TLR agonists, as well as across classes, such as TLR agonists combined with CLR or NLR agonists [42,43]. Many live and inactivated vaccines including BCG, Typhim, Influvac, and YF-17D engage multiple PRR, which contributes to their immunogenicity and protective efficacy [34,44]. Seminal work by Napolitani et al. demonstrated that conditioning APCs with multiple TLR agonists enhanced their ability to prime TH1 responses in vitro [16]. Enhanced activity may arise from activation of additional APC types based on receptor expression patterns, augmentation of APC cytokine secretion, or synergistic signaling events in APCs downstream of the different receptors [23]. For example, TLR4 signals through both MyD88 and TRIF, whereas TLR7, 8 and 9 only signal through MyD88. Based on the results of pairwise TLR agonist combinations it has been proposed that signaling through both MyD88 and TRIF were necessary for increased cytokine production and T cell priming [16,18]. Indeed in the absence of either TRIF or MyD88, synergistic production of cytokines by dendritic cells stimulated with polyI:C and either MALP-2 or CpG was abolished [17]. MyD88 was necessary for the increased CD8+ T cell response seen with peptide immunization adjuvanted with MALP-2 and polyI:C [17]. In vitro activation of dendritic cells with combinations of TLR3 and TLR9, TLR4 and TLR7, or TLR2 and TLR3 agonists enhanced their ability to induce CD8+ T cell responses when transferred in vivo [17,38,40]. Despite the plethora of data showing the efficacy of single PRR agonists as vaccine adjuvants, there is surprisingly little data assessing the
effects of combining PRR agonists for in vivo immunization. We have shown that combining TLR4 and TLR9 agonists enhanced the efficacy of a therapeutic vaccine against Leishmaniasis [22]. Others have found that combining a TLR3 agonist with either a TLR2 or TLR9 agonist, or combining three agonists together can enhance vaccines against M. tb. and HIV [17,19].

We find that the combination of GLA and CpG enhances the production of IL-12 by macrophages ex vivo. This correlates well with the increased magnitude of the T H1 response to vaccination with both adjuvants. In turn this enhanced CD4 + T cell response correlated with improved protection against aerosolized M. tb. both in terms of a reduction in bacterial burden and decreased lung pathology. Surprisingly this adjuvant synergy was evident in the absence of TRIF, even though TRIF was necessary for the adjuvant activity of GLA-SE in the absence of CpG. This suggests that although GLA driven MyD88 signaling is not sufficient to enhance T H1 production in the absence of TRIF, it is sufficient to achieve adjuvant activity of GLA-SE in the absence of CpG. This suggests that although GLA driven MyD88 signaling is not sufficient to enhance T H1 production in the absence of TRIF, it is sufficient to augment the MyD88 signaling outcomes driven by CpG triggering of TLR9. Although the exact nature of this synergism in the absence of TRIF is uncertain, it is reasonable to hypothesize that it is dependent on enhanced IL-12 production, which we find to be TRIF-independent when splenic macrophages are stimulated with GLA and CpG. This latter finding expands the possible combinations of TLR agonists that may be beneficial for enhanced adjuvant activity.

We were surprised that the GLA and CpG synergized to enhance IL-12 production by splenic macrophages in a TRIF-independent fashion. A previous study found that TRIF was necessary for enhanced IL-12 production by bone marrow derived dendritic cells stimulated with combinations of LPS and CpG [24]. The difference in our findings and this study may stem from how the particular cell type and preparation or possible differences between LPS and GLA activity, although both signal via TLR4. The discordance between our findings that TRIF is dispensable for adjuvant synergy and previous findings that inclusion of a TRIF-dependent agonist is necessary for adjuvant synergy may be due to differences in model systems. Specifically we have examined the magnitude of the polyclonal T H1 response as the measure of adjuvant activity following repeated in vivo immunization, whereas previous studies focused on in vitro cytokine production by stimulated APCs and/or the ability of APCs stimulated with combinations of TLR agonists in vitro to prime T cell responses in vivo [16,18,33,40]. Additionally the TRIF-dependence for the synergistic activity of multiple TLR ligands was inferred based on the combinations of stimulants that did or did not enhance activity, rather than testing for adjuvant cooperation in TRIF-deficient models as we have done here.

In summary combining two distinct TLR agonists into an adjuvanted subunit vaccine doubled the magnitude of the T H1 response and enhanced the protective efficacy. Until an effective vaccine against TB is developed and tested clinically in efficacy studies it will be impossible to validate correlates of protection. Our current results provide a system to test whether the magnitude of antigen specific CD4 + T cells is an important factor for vaccine efficacy in the control of M. tb. either for prevention of infection or limitation of active disease.

### Supporting Information

Figure S1 Representative cytokine gating upon ex-vivo restimulation. Spleenocytes from a C57BL/6 mouse immunized with ID93+GLA were either unstimulated (top row) or restimulated with ID93 in the presence of Breelflin A. Cells were gated as singlets, lymphocytes, CD44 + CD4 + CD8 + T cells. (TIF)

Figure S2 ID93 adjuvanted with GLA and CpG limit lung pathology following M. tb. infection. Mice were immunized and challenged with a low dose of aerosolized M. tb. four weeks later. Four weeks after infection lung sections were stained with H&E to evaluate pathology. Data are representative of three experiments with similar results with four mice per group. (TIF)

### Acknowledgments

We thank Heather Davis for insightful discussions. We thank Valerie Reese, David Argilla, Charles Davis, Jazel Dolores, Traci Mikasa, Susan Lin, Sandra Sivananthan and Millie Fung for excellent technical assistance.

### Author Contributions

Conceived and designed the experiments: MTO TEH. Performed the experiments: MTO EAB TEH. Analyzed the data: MTO EAB TEH. Contributed reagents/materials/analysis tools: JJM CBF. Wrote the paper: MTO SGR RNC.

### References


